Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexagene Holdings Inc V.LXG


Primary Symbol: LXXGQ

Healthcare Medical Devices
Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.


GREY:LXXGQ - Post by User

Lexagene Holdings Inc > LXG's technology needed more than ever for Covid-19
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(18)
•••
Comment by Investor62on May 17, 2020 4:43am
102 Views
Post# 31039256

RE:RE:RE:RE:RE:LXG's technology needed more than ever for Covid-19

RE:RE:RE:RE:RE:LXG's technology needed more than ever for Covid-19@letsdoit: it would be desirable if you would substantiate your statements! On what assumption do you assume that production will not start until 2021? A reply like: “not sure to be honest rag LOL» another post, which neither passes on sound knowledge nor gives away any relevant information about the company – waste of time!
 
In the last available press release (April 16, 2020), Dr Jack Regan made the following statement: LexaGene plans to launch its multiplex, PCR-based LX Analyzer as its flagship product, targeting decentralized testing facilities in the clinical, veterinary, and food safety markets during Q3 of this year.
Can be verified:
https://lexagene.com/release/2020/lexagene-files-patent-application-for-expanded-capabilities/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities